Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (748)	10/8/2003 2:15:38 PM
From: Icebrg	Read Replies (1) \| Respond to of 2240

>>Surely we now know it isn't quite as easy as that (or there'd be a lot more in the clinic by now) ? >> Relatively seen. I think the problems getting new mAbs into the clinics have more to do with biology than with the know-how needed to create suitable mAbs. Medarex is IMHO a good example of this. They have their 20+ joint ventures with different companies, but there has been no mAb going into the clinic yet from all those efforts. Has this been because of the difficulties in finding relevant targets or due to the fact that they have not been able to create the appropriate mAbs? I tend to think that the problems has more to do with the biology than with the mAbs. Something that IMHO has been confirmed by Abgenix who now refuses to take their mAbs out of the testing grounds before they have found an expert to guide them. Erik